期刊文献+

多水平模型在临床试验中心效应分析中的研究 被引量:3

Multilevel Models in the Analysis of Center Effect in Clinical Trials
原文传递
导出
摘要 多水平模型是既适用于计量资料、又适用于二分类或多分类资料的统计方法。本文通过对各类型的实例数据,分别应用多水平模型、协方差分析和CMH卡方检验方法进行分析,探讨多水平模型在多中心临床试验中心效应分析中的应用。结果表明,在计量资料的中心效应分析中,协方差分析较多水平模型更容易发现中心效应;对分类资料的中心效应,多水平模型更为敏感。可见不同分析方法对中心效应的分析结果不相同,在实际运用中应结合数据自身的结构特点和研究目的,并根据各种方法的适用条件选择分析方法。 Multilevel models are applicable to both the quantitative data and categorical variables. We used the meth- ods, including the multilevel models, analysis of covariance and CMH chi-square test, to analyse different types of data, to explore the application of multilevel models in the analysis of the multicenter clinical trial center effect. The results showed that the analysis of covariance is more sensitive to find the center effect for quantitative data, while multilevel models are more sensitive to categorical variables. It can be seen that results with different analytical meth- ods for center effect are not the same, and the most appropriate method should be selected in accordance with the characteristics of data, the objective of research, and the applicable conditions of the various methods in practicaluse.
出处 《生物医学工程学杂志》 EI CAS CSCD 北大核心 2014年第3期632-636,共5页 Journal of Biomedical Engineering
关键词 多水平模型 临床试验 中心效应 协方差分析 CMH卡方检验 multilevel models clinical trial center effect analysis of covariance CMH chi-square test
  • 相关文献

参考文献12

二级参考文献34

  • 1王文,马丽媛,邹效漫.国际多中心临床试验的监查[J].中国临床药理学与治疗学,2004,9(7):835-837. 被引量:9
  • 2于浩,陈峰.临床试验中中心效应的评价及处理方法[J].中国临床药理学与治疗学,2004,9(9):1073-1076. 被引量:8
  • 3李晓松.多水平统计模型[M].四川科学技术出版社,1999.90-130.
  • 4The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients ran- domized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti- hypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)[J]. JAMA, 2002,288:2981--2997.
  • 5Sever PS, Poulter NR, Dahlof B, et al. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension [J]. J Hypertens, 2009,27(5) : 947--954.
  • 6Lisheng L, Yuqing Z, Guozhang L, et al. The Felodipine Event Reduction (FEVER) study; A randomized long-term placebo controlled trial in Chinese hypertensive patients [J]. J Hypertens, 2005,23(12) : 2157--2172.
  • 7Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial[J]. Lancet, 2004,363 (9426) : 2022-- 2031.
  • 8Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular e vents through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk[J]. Blood Pressure, 2007,16 (1): 13-- 19.
  • 9国家食品药品监督管理局令(第3号).药物临床试验质量管理规范[S].2003年8月6号.
  • 10[1]国家食品药品监督管理局.药品注册管理办法[S].2000

共引文献33

同被引文献28

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部